Is Short-Term Palliative Care Cost-Effective in Multiple Sclerosis Is Short-Term Palliative Care Cost-Effective in Multiple Sclerosis? A Randomized Phase II Trial  Irene J. Higginson, BMedSci, BMBS, PhD, FFPM, FRCP, Paul McCrone, BSc Hons, MSc, PhD, Sam R. Hart, BA, Rachel Burman, MA, FRCP, Eli Silber, MD, FCP(Neuro)SA, Polly M. Edmonds, MBBS, MRCP, FRCP  Journal of Pain and Symptom Management  Volume 38, Issue 6, Pages 816-826 (December 2009) DOI: 10.1016/j.jpainsymman.2009.07.002 Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 1 CONSORT diagram showing the flow of patients through the study. N (N)=patients remaining in study (interviews actually completed at this stage). A small number of interviews were missed because the patient was unavailable (away/in hospital) and one error in scheduling. Journal of Pain and Symptom Management 2009 38, 816-826DOI: (10.1016/j.jpainsymman.2009.07.002) Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 2 Cost-effectiveness analysis at 0–12 weeks for PCT compared with control for (A) POS-8 and (B) ZBI. Dots to the right of the axis indicate improved outcomes; dots below the horizontal axis show lower costs. Therefore, dots in the lower right quadrant show both improved outcomes and lower costs, and those in the upper left quadrant show worse outcomes and higher costs. Journal of Pain and Symptom Management 2009 38, 816-826DOI: (10.1016/j.jpainsymman.2009.07.002) Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions